Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Abnormal brain rhythms tied to problems with thinking in schizophrenia

  • Neuropathy: Relief for diabetics with painful condition

  • Exposure to endocrine disruptors during pregnancy affects the brain two generations later, rat study shows

  • Autistic features linked to prenatal exposure to commonly found fire retardants, phthalates

  • Seven strategies to advance women in science

  • Mutation in APC2 gene causes Sotos features

  • From chick to bedside: Removing the Wnt barrier

  • Drug to control appetite could also fight anxiety

  • Oxytocin nasal spray causes men to eat fewer calories

  • Human brains age less than previously thought

  •